Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szoke

Showing results (241-250 of 287) with videos related to

Pageof 29
Sort By:
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockersL Y Hu, T R Ryder, M F Rafferty, et al.
Frontiers in Microbiology|August 29, 2022
Genomic and virologic characterization of samples from a shipboard outbreak of COVID-19 reveals distinct variants within limited temporospatial parametersRegina Z Cer, Logan J Voegtly, Bishwo N Adhikari, et al.
Particle and Fibre Toxicology|May 13, 2018
Lipophilic components of diesel exhaust particles induce pro-inflammatory responses in human endothelial cells through AhR dependent pathway(s)Bendik C Brinchmann, Tonje Skuland, Mia H Rambøl, et al.
Journal of Medicinal Chemistry|October 9, 1999
Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic propertiesL Y Hu, T R Ryder, M F Rafferty, et al.
Oncogene|June 16, 2009
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumorsD Chitale, Y Gong, B S Taylor, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Drug Design and Discovery|August 6, 2000
Neuronal N-type calcium channel blockers: a series of 4-piperidinylaniline analogs with analgesic activityL Y Hu, T R Ryder, M F Rafferty, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2011
Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's diseaseMartin L Neitzel, Danielle L Aubele, Jennifer L Marugg, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Pageof 29

Showing results (241-250 of 287) with videos related to

Sort By:
Pageof 29
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockersL Y Hu, T R Ryder, M F Rafferty, et al.
Frontiers in Microbiology|August 29, 2022
Genomic and virologic characterization of samples from a shipboard outbreak of COVID-19 reveals distinct variants within limited temporospatial parametersRegina Z Cer, Logan J Voegtly, Bishwo N Adhikari, et al.
Particle and Fibre Toxicology|May 13, 2018
Lipophilic components of diesel exhaust particles induce pro-inflammatory responses in human endothelial cells through AhR dependent pathway(s)Bendik C Brinchmann, Tonje Skuland, Mia H Rambøl, et al.
Journal of Medicinal Chemistry|October 9, 1999
Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic propertiesL Y Hu, T R Ryder, M F Rafferty, et al.
Oncogene|June 16, 2009
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumorsD Chitale, Y Gong, B S Taylor, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Drug Design and Discovery|August 6, 2000
Neuronal N-type calcium channel blockers: a series of 4-piperidinylaniline analogs with analgesic activityL Y Hu, T R Ryder, M F Rafferty, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2011
Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's diseaseMartin L Neitzel, Danielle L Aubele, Jennifer L Marugg, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Pageof 29